BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...trials.The South San Francisco company markets its Tapestri...
...December 2018, the company has added to Tapestri...
...cancer centers and third-party CROs have used Tapestri...
BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

...cells Mission Bio Inc. is collaborating with BioLegend Inc. to add protein analysis to its Tapestri...
...protein from single cells. Along with detecting single nucleotide variants and copy number variations, the Tapestri...
BioCentury | Aug 23, 2019
Preclinical News

Aug. 23 Preclinical Quick Takes: Mission Bio launches new feature in single-cell analysis platform; plus CRISPR-triggered hydrogel cargo release and more

...Inc. (South San Francisco, Calif.) launched Copy Number Analysis, a new feature integrated into its Tapestri...
...copy number variants along with single nucleotide variants within single cancer cells. Mission Bio markets Tapestri...
BioCentury | Dec 14, 2018
Finance

Mission: Mainstream

...take the product past the early adopters.” Ursheet Parikh, Mayfield Mission launched its platform, dubbed Tapestri...
...to their drugs up against the ones not expected to respond,” Silver told BioCentury. Since Tapestri’s...
...UCSF in 2014 with exclusive, worldwide rights to Tapestri. Virginia Li, Assistant Editor Mission Bio Inc. Mayfield single-cell DNA analysis Tapestri...
BioCentury | Dec 14, 2018
Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

...its single-cell DNA analysis platform, dubbed Tapestri, and expand into global markets. Mission Bio markets Tapestri...
...spun out of University of California San Francisco in 2014 with exclusive, worldwide rights to Tapestri...
...it launched last year. Mission Bio Inc., South San Francisco, Calif. Virginia Li Mission Bio Inc. single-cell DNA analysis Tapestri...
BioCentury | Dec 13, 2018
Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

...its single-cell DNA analysis platform, dubbed Tapestri, and expand into global markets. Mission Bio markets Tapestri...
...with exclusive, worldwide rights to Tapestri, which it launched last year. Virginia Li Mission Bio Inc. single-cell DNA analysis Tapestri...
BioCentury | Dec 29, 2016
Politics, Policy & Law

Leadership and responsibility

In the presidential election, a significant proportion of American voters, feeling unspoken for and left behind by establishment politicians and policies, expressed their displeasure and desire for change. The campaign also gave voice to disturbing...
BioCentury | Aug 25, 2008
Company News

Advanced Cancer Therapeutics management update

Advanced Cancer Therapeutics LLC , Louisville, Ky. Business: Cancer Hired: Gilles Tapolsky as CSO, formerly VP of product development at Tapestry Pharmaceuticals Inc. WIR Staff cancer...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 12 mos ended 12/31 1/15/08 NitroMed (NASDAQ:NTMD) 89% to 10 $31.4 0.96 12/31/07 $32.8 Exploring strategic alternatives; discontinuing sales and...
BioCentury | Feb 18, 2008
Company News

Tapestry Pharmaceuticals cancer news

Tapestry began filing for Chapter 11 bankruptcy and reduced its headcount by 22 (65%) to 12. Tapestry will continue its clinical trials of TPI 287, a third-generation taxane in Phase II testing to treat hormone-refractory...
Items per page:
1 - 10 of 48
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...trials.The South San Francisco company markets its Tapestri...
...December 2018, the company has added to Tapestri...
...cancer centers and third-party CROs have used Tapestri...
BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

...cells Mission Bio Inc. is collaborating with BioLegend Inc. to add protein analysis to its Tapestri...
...protein from single cells. Along with detecting single nucleotide variants and copy number variations, the Tapestri...
BioCentury | Aug 23, 2019
Preclinical News

Aug. 23 Preclinical Quick Takes: Mission Bio launches new feature in single-cell analysis platform; plus CRISPR-triggered hydrogel cargo release and more

...Inc. (South San Francisco, Calif.) launched Copy Number Analysis, a new feature integrated into its Tapestri...
...copy number variants along with single nucleotide variants within single cancer cells. Mission Bio markets Tapestri...
BioCentury | Dec 14, 2018
Finance

Mission: Mainstream

...take the product past the early adopters.” Ursheet Parikh, Mayfield Mission launched its platform, dubbed Tapestri...
...to their drugs up against the ones not expected to respond,” Silver told BioCentury. Since Tapestri’s...
...UCSF in 2014 with exclusive, worldwide rights to Tapestri. Virginia Li, Assistant Editor Mission Bio Inc. Mayfield single-cell DNA analysis Tapestri...
BioCentury | Dec 14, 2018
Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

...its single-cell DNA analysis platform, dubbed Tapestri, and expand into global markets. Mission Bio markets Tapestri...
...spun out of University of California San Francisco in 2014 with exclusive, worldwide rights to Tapestri...
...it launched last year. Mission Bio Inc., South San Francisco, Calif. Virginia Li Mission Bio Inc. single-cell DNA analysis Tapestri...
BioCentury | Dec 13, 2018
Financial News

Mission Bio raises $30M series B to expand Tapestri’s reach

...its single-cell DNA analysis platform, dubbed Tapestri, and expand into global markets. Mission Bio markets Tapestri...
...with exclusive, worldwide rights to Tapestri, which it launched last year. Virginia Li Mission Bio Inc. single-cell DNA analysis Tapestri...
BioCentury | Dec 29, 2016
Politics, Policy & Law

Leadership and responsibility

In the presidential election, a significant proportion of American voters, feeling unspoken for and left behind by establishment politicians and policies, expressed their displeasure and desire for change. The campaign also gave voice to disturbing...
BioCentury | Aug 25, 2008
Company News

Advanced Cancer Therapeutics management update

Advanced Cancer Therapeutics LLC , Louisville, Ky. Business: Cancer Hired: Gilles Tapolsky as CSO, formerly VP of product development at Tapestry Pharmaceuticals Inc. WIR Staff cancer...
BioCentury | Apr 7, 2008
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 12 mos ended 12/31 1/15/08 NitroMed (NASDAQ:NTMD) 89% to 10 $31.4 0.96 12/31/07 $32.8 Exploring strategic alternatives; discontinuing sales and...
BioCentury | Feb 18, 2008
Company News

Tapestry Pharmaceuticals cancer news

Tapestry began filing for Chapter 11 bankruptcy and reduced its headcount by 22 (65%) to 12. Tapestry will continue its clinical trials of TPI 287, a third-generation taxane in Phase II testing to treat hormone-refractory...
Items per page:
1 - 10 of 48